COX-2 inhibitors as adjunctive therapy in schizophrenia

Bibliography

• MENNINGER KA: Psychoses associated influenza. J. Am. Med. Assoc. (1919) 72:235–241.
   Google Scholar
• •One of the first descriptions of virus-induced psychoses during an influenza epidemy.
   Google Scholar
• MENNINGER KA: Influenza and schizophrenia. An analysis of postinfluenza 'dementia praecox' as of 1918 and five years later. Am. Psychiatry (1926) 5:469–529.
   Google Scholar
• MENNINGER KA: The schizophrenia syndrome as a product of acute infectious. Arch. Neurol. Psychiatry (1928) 20:464–481.
   Google Scholar
• WISE TN, LA BUFFE FP, GRANGER ST: Meningo encephalitis presenting as an acute paranoid psychosis. Int. j Psychiatry Med. (1977) 8:405–414
   PubMed Web of Science ®Google Scholar
• SCHLITT M, LAKEMAN FD, WHITLEY RJ: Psychosis and herpes encephalitis. South Med. 1 (1985) 78:1347-1350.
   Google Scholar
• HOWARD JS 3rd: Herpes encephalitis, schizophrenia and the crossroad of psychiatry. Integr. Physiol Behav. ScL (1996) 31:219–223.
   PubMed Web of Science ®Google Scholar
• KROGER KW: Lupus erythematodes und Zentralnervensystem. Nervenarzt (1984) 55:165–172.
   PubMedGoogle Scholar
• RAPS A, ABRAMOVICH Y, ASSAEL M: Relation between schizophrenic-like psychosis and Sjögren Syndrome (SS). Isr. Psychiatry RelaL Sci. (1986) 23:321–324.
   PubMed Web of Science ®Google Scholar
• MOLLER N, GIZYCKI-NIENHAUS B, GUNTHER W et al.: Depression as a possible cerebral manifestation of scleroderma: immunological findings in serum and CSE Biol. Psychiatry (1992) 31:1151–1156.
   Web of Science ®Google Scholar
• KURTZ G, MOLLER N: The syndrome and psychosis. Am. J. Psychiatry (1994) 151:1841–1842.
   PubMed Web of Science ®Google Scholar
• KORSCHENHAUSEN D, HAMPEL H, ACKENHEIL M et al.: Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr: Res. (1996) 19:103–109.
   PubMed Web of Science ®Google Scholar
• •Post-mortem brain tissue evidence for an inflammatory process in schizophrenia.
   Google Scholar
• WILDENAUER D, HOECHTLEN W: Liquorproteine bei psychiatrischen Erkrankungen. In: Psychoimmunologie. WP Kaschka, NH Aschauer (Eds), Thieme, Stuttgart, NY (1990):75–81.
   Google Scholar
• O'BANION MK: Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol (1999) 13:45–82.
   PubMed Web of Science ®Google Scholar
• VANE JR, BOTTING RM: Mechanism of action of aspirin-like drugs. Semin. Arthritis Rheum. (1997) 6\(Suppl. 1):2–10.
   Google Scholar
• HILKENS CM, SNIJDERS A, SNIJDEWINT FG et al.: Modulation of T-cell cytokine secretion by accessory cell-derived products. Ear: Respir. J. (1996) Suppl. 22:90s–94s.
   Google Scholar
• YAMAGATA K, ANDREASSON KI, KAUFMANN WE et al: Expression of a mitogen-inductible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron (1993) 11:371–386.
   PubMed Web of Science ®Google Scholar
• ••This paper shows that COX-2 is expressed in the brain.
   Google Scholar
• KAM PC, SEE AU: Cyclo-oxygenase isoenzymes: physiological and role. Anaesthesia (2000) 55:442–449.
   PubMed Web of Science ®Google Scholar
• KAUFMANN WE, ANDREASON KI, ISAKSON PC et al.: Cyclooxygenases and the central nervous system. Prostaglandins (1997) 54:601–624.
   PubMed Web of Science ®Google Scholar
• MATSUMURA K, WATANABE Y, IMAI-MATSUMURA K et al.: Mapping of prostaglandin e2 binding sites in rat brain using quantitative autoradiography. Brad) Res. (1992) 581:292–298.
   PubMed Web of Science ®Google Scholar
• FRANK E, SWARTZ HA, KUPFER DJ: Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol. Psychiatry(2000) 43:593–604.
   Google Scholar
• KAUFMANN WE, WORLEY PF, PEGG J et al.: Cox-2, a synaptically induced enzyme, is expressed by excitatory neurons at post-synaptic sites in rat cerebral cortex. Proc. Natl Acad. Sci. USA (1996) 93:2317–2321.
   PubMed Web of Science ®Google Scholar
• BREDER CD, SAPER CB: Expression ofinductible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brad) Res. (1996) 713:64–69.
   PubMed Web of Science ®Google Scholar
• ADAMS J, COLLACO-MORAES Y, DE BELLEROCHE J: Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation.. (1996) 66:6–13.
   Google Scholar
• PLANAS AM, SORIANO MA, JUSTICIA C et al.: Introduction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. NeurosL Lett. (1999) 275:141–144.
   PubMed Web of Science ®Google Scholar
• PLANAS AM, SORIANO MA, RODRIGUEZ-FARR E et al. : Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. NeuroscL Lett. (1995) 200:187–190.
   PubMed Web of Science ®Google Scholar
• TOCCO G, FREIRE MJ, SCHREIBER SS et al.: Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implication for Alzheimer's disease. Exp. Nemo]. (1997) 144:339–349.
   PubMed Web of Science ®Google Scholar
• BREDER CD, DEWITT D, KRAIG RP: Characterization of inducible cyclooxygenase in rat brain. J. Comp. Nemo]. (1995) 355:296–315.
   PubMed Web of Science ®Google Scholar
• WORLEY PF, CHRISTY BA, NAKABEPPU Yet al.: Constitutive expression of Zif268 in neocortex is regulated by synaptic activity. Proc. Nati Acad. Sci. USA (1991) 88:5106–5110.
   Google Scholar
• FAGARASAN MO, AISEN PS : I1-1 and anti-inflammatory drugs modulate A-I3 cytotoxicity in PC12 cells. Brad) Res. (1996) 723:231–234.
   PubMed Web of Science ®Google Scholar
• CAMPBELL IL, ABRAHAM CR, MASLIAH E et al.: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA (1993) 90:10061–10065
   PubMed Web of Science ®Google Scholar
• •A study focusing on the role of IL-6 in CNS disorders.
   Google Scholar
• LEONARD BE: The immune system, and the action of antidepressants.. Neuropsychopharmacol Biol. PsychiaL (2001) 25:767–780.
   PubMed Web of Science ®Google Scholar
• •A comprehensive overview of the relationship between immunity and depression.
   Google Scholar
• RAPOPORT SI, BOSETTI F: Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry. (2002) 59:592–596.
   PubMed Web of Science ®Google Scholar
• BOSETTI F, WEERASINGHE GR, ROSENBERGER TA et al.: Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cycloocygenase-1 and -2 in rat brain.(2003) 85:690–696.
   Google Scholar
• BOSETTI F, RINTALA J, SEEMANN R et al.: Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin e2 concentration in rat brain. Ma Psychiatry (2003) 7:845–850.
   Google Scholar
• DAS I, KHAN NS: Increased arachidonic acid induced platelet chemoluminiscence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins, Leukot. EssenL Fatg Acids (1998) 58:165–168.
   PubMed Web of Science ®Google Scholar
• WILLARD LB,-WEGRZYNIAK B, DANYSZ W et al.: The cytotoxicity of chronic neuroninflammation upon basal forebrain cholingergic neurons of rats can be attenuated by gluatamatergic atagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. (2000) 134:58–65.
   Google Scholar
• ARAKI E, FORSTER C, DUBINSKY J et al.: Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures form lipopolysaccharide-induced neurotoxicity. Stroke (2001) 32:2370–2375.
   PubMed Web of Science ®Google Scholar
• HEWETT SJ, ULIASY TF, VIDWANS AS et al.: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. Phantom]. Exp. Ther. (2000) 293:417–425.
   PubMed Web of Science ®Google Scholar
• COLE DJ, PATEL PM, SCHELL RM et al.: Brain eicosanoid levels during temporary focal ischemia in rats: a microdialysis study. Neurosurg. Anesthesia (1993) 5:41–47.
   PubMed Web of Science ®Google Scholar
• GARCIA J, YOSHIDA Y, CHEN H et al.:Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Arn. J. PathoL (1993) 142:623–635.
   PubMed Web of Science ®Google Scholar
• TEISMANN P, TIEU K, CHOI DK et al: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. PNAS (2003) 100:5473–5478
   PubMed Web of Science ®Google Scholar
• KUNZ T, OLIW EH: The selective cyclooxygenase-2 inhibitor rofecoxib reduces keinate-induced cell death in the rat hippocampus. Ear: I Neurosci (2001) 13:569–575.
   PubMed Web of Science ®Google Scholar
• •The role of COX-2 inhibition in neuroprotection.
   Google Scholar
• AISEN PS, SCHAFER KA, GRUNDMAN M et al.: Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA (2003) 289:2819–2826.
   PubMed Web of Science ®Google Scholar
• McGEER PL: Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drugs Aging (2000) 17:1–11.
   Google Scholar
• LAUNER LJ: Non-steroidal anti-inflammatory drugs and Alzheimer's disease: what next? JAMA (2003) 289:2865–2867.
   PubMed Web of Science ®Google Scholar
• •Discusses the methodological pitfalls regarding the studies of COX-2 inhibitors in Alzheimer's disease.
   Google Scholar
• HILKENS CM, SNIJDERS A, SNIJDEWINT FG et al.: Modulation of T-cell cytokine secretion by accessory cell-derived products. Ear: Respir. 1 (1996) 22(Suppl.):90s–94s.
   Google Scholar
• HINSON RM, WILLIAMS JA, SHACTER E: Elevated interleukin 6 is induced by prostaglandin e2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sri. USA (1996) 93:4885–4890.
   PubMed Web of Science ®Google Scholar
• ••The paper describes the relationshipbetween IL-6, PGE2 and COX–2.
   Google Scholar
• STOLINA M, SHARMA S, LIN Y et al.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. (2000) 164:361-370.
   Google Scholar
• HARRIS SG, PADILLA J, KOUMAS Let al.: Prostaglandins as modulators of immunity. Trends bninuna (2002) 23:144–150.
   Google Scholar
• COTTER D, TAKEI N, FARRELL M et al.: Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus? Schizophi: Res (1995) 16:233–241.
   Google Scholar
• IMPAGNATIELLO F, GUIDOTTI AR, PESOLD C et al.: A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Nati Acad. Sri. USA (1998) 95:15718–15723.
   PubMed Web of Science ®Google Scholar
• KOSUGI I, SHINMURA Y, H et al.: Cytomegalovirus infection of the central nervous system stem cells from mouse embryo: a model for developmental brain disorders induced by cytomegalovirus. Lab. Invest. (2000) 80:1373–1383.
   PubMed Web of Science ®Google Scholar
• •A model for virus-induced developmental brain disorders. Schizophrenia is thought to be such a disorder.
   Google Scholar
• RUBIN SA, PLETNIKOV M, ONE KM: Comparison of the neurovirulence of a vaccine and a wild-type mumps virus strain in the developing rat brain. J. Virol (1998) 72:8037–8042.
   PubMed Web of Science ®Google Scholar
• RAMIREZ JC, FAIREN A, JM: Parvovirus minute virus of mice strain i multiplication and pathogenesis in the newborn mouse brain are restricted to proliferative areas and to migratory cerebellar young neurons. J. Vita (1996) 70:8109–8116.
   Google Scholar
• LYCKE E, ROOS BE: Virus infections in infant mice causing persistent impairment of turnover of brain catecholamines. Neura Sri. (1975) 26:49–60.
   Web of Science ®Google Scholar
• •This work describes the relationship between virus-infection during development and disturbance in catecholarnin metabolism.
   Google Scholar
• ZALCMAN S, GREEN-JOHNSON JM, MURRAY L et al.: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brant Res. (1994) 643:40–49.
   PubMed Web of Science ®Google Scholar
• ••Experiments showing the effects of pro-inflammatory cytokines on doparnin-mediated and 5-HT-mediated metabolism the brain.
   Google Scholar
• DANTZER R: Cytokine-induced sickness behavior: Where do we stand? Brea Behav. Inman. (2001) 15:7–24.
   Web of Science ®Google Scholar
• ••Sickness behaviour as a model for clinicaldepression.
   Google Scholar
• DANTZER R, BLUTHE R, N et al.: Cytokine effects on behavior. In: Psychoneurammunology Ord Edition Volume 2). R Ader, DL Felten, N Cohen (Eds), Academic Press, San Diego, USA (2001):373–382.
   Google Scholar
• BAKHIET M, TJERNLUND A, MOUSA A et al.: RANTES promotes growth and survival of human first-trimester forebrain aastrocytes. Nat. Cell. Biol. (2001) 3:150–157.
   PubMed Web of Science ®Google Scholar
• GADIENT RA, OTTEN UH:-6 (IL-6)-a molecule with both beneficial and destructive potentials. Frog. NeurobioL (1997) 52:379–390.
   Google Scholar
• KREUTZBERG GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci. (1996) 19:312–318.
   PubMed Web of Science ®Google Scholar
• KRAKOWSKI ML, OWENS T: The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis. Ea Immuna (1997) 27:2840–2847.
   PubMed Web of Science ®Google Scholar
• ALOISI F, RIA F, ADORINI L: Regulation T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immuna Today (2000) 21:141–147.
   PubMedGoogle Scholar
• •Overview of the type-1 and -2 immune response in the brain.
   Google Scholar
• MOLLER N, ACKENHEIL M: and the cytokine-network in the CNS: implications for psychiatric disorders. Frog. Neuropsychopharmaca Biol. Psychiat. (1998) 22:1–33.
   PubMed Web of Science ®Google Scholar
• YOLKEN RH, TORREY EF: Viruses, schizophrenia, and bipolar disorder. Clin. Microbia Rev (1995) 8:131–145.
   PubMed Web of Science ®Google Scholar
• VILLEMAIN F, CHATENOUD L, GALINOWSKI A et al.: Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry (1989) 146:609–616.
   PubMed Web of Science ®Google Scholar
• GANGULI R, BRAR JS, KR et al.: Mitogen-stimulated interleukin 2 production in never-medicated, first episode schizophrenics - the influence of age of onset and negative symptoms. Arch. Gen. Psychiatry (1995) 52:878.
   PubMedGoogle Scholar
• HORNBERG M, AROLT V, WILKE I et al.: Production of interferons and lymphokines in leukocyte cultures of with schizophrenia. Schizophrenia Res. (1995) 15:237–242.
   Google Scholar
• •One of the studies showing a decreased type-1 immune activation in schizophrenia.
   Google Scholar
• BESSLER H, LEVENTAL Z, KARP L et al.: Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol. Psychiatry (1995) 38:297–302.
   PubMed Web of Science ®Google Scholar
• CAZZULLO CL, SCARONE S, GRASSI B et al.: Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Frog. Neuro-Psychopharmacol Biol. Psychiatry (1998) 22:947–957.
   PubMed Web of Science ®Google Scholar
• ROTHERMUND M, AROLT V, WEITZSCH CH et al.: Production of cytokines in acute schizophrenic psychosis. Biol. Psychiatry (1998) 22:1294–1297.
   Google Scholar
• WILKE I, AROLT V, Met al.: Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Ear: Arch. Psychiatry Clin. Neurosci. (1996) 246:279–284.
   Google Scholar
• RIEDEL M, STRASSNIG M, SPELLMANN I, SIKORSKI CH, MOLLER HJ, MOLLER N: Decreased cutaneous immune response in schizophrenic patients. Ear: Arch. Psychiatry Clin. Neurosci. (submitted).
   Google Scholar
• SCHWARZ MJ, RIEDEL M, M, MOLLER N: Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry (2000) 47:29–33.
   PubMed Web of Science ®Google Scholar
• GANGULI R, YANG Z, SHURIN Get al.: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. (1994) 51:1–10.
   Google Scholar
• •One of the studies showing an increased IL-6 concentration in schizophrenia.
   Google Scholar
• MAES M, BOSMANS E, CALABRESE J et al.: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood-stabilizers.. Res. (1995) 29:141–152.
   Google Scholar
• FROMMBERGER UH, BAUER J, HASELBAUER P et al.: (1997) Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Ear: Arch. Psychiatry Clin. Neurosci. 247: 228–233.
   Google Scholar
• LIN A, KENIS G, BIGNOTTI S et al.: The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophrenia Res. (1998) 32:9–15.
   PubMed Web of Science ®Google Scholar
• VAN KAMMEN DP, McALLISTER-SISTILLI CG, KELLEY ME: Relationship between immune and behavioral measures in schizophrenia. In: Current Update M Psychoimmunology G Wieselmann (Ed.), Springer Verlag Wien, NY, USA (1997):51–55.
   Google Scholar
• MITTLEMAN BB, CASTELLANOS FX, JACOBSON LK et al.: Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol (1997) 159:2994–2999.
   PubMed Web of Science ®Google Scholar
• SCHWARZ MJ, CHIANG S, MOLLER N etal.: T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. (2001) 15:340–370.
   Google Scholar
• •This paper summarises the type-1 and -2 immune response hypothesis in psychiatric disorders.
   Google Scholar
• MOLLER N, ULMSCHNEIDER M, SCHEPPACH C et al.: COX-2 inhibition as treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Ear. Arch. Psychiatry Clin. Neurosci. (2004) 254:14–22.
   PubMed Web of Science ®Google Scholar
• POLLMÄCHER T, HAACK M, A et al.: Effects of antipsychotic drugs to cytokine networks. I Psychiat. Res. (2000) 34:369–382.
   PubMed Web of Science ®Google Scholar
• MOLLER N, EMPEL M, RIEDEL M et al.: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Ear. Arch. Psychiatry Clin. Neurosci. (1997) 247:308–313.
   PubMed Web of Science ®Google Scholar
• •A paper showing the influence of antipsychotic therapy on the type-1/-2 immune response.
   Google Scholar
• MOLLER N, HADJAMU M, RIEDEL M et al.: The adhesion-molecule receptor expression on T helper cells increases during treatment with neuroleptics and is related to the blood-brain barrier permeability in schizophrenia. Am. Psychiatry(1999) 156:634–636.
   PubMed Web of Science ®Google Scholar
• SCHWARZ MJ, ACKENHEIL M, RIEDEL M et al.: Blood-CSF-barrier impairment as indicator for an immune process in schizophrenia. Neurosci. Letters (1998) 253:201–203.
   PubMed Web of Science ®Google Scholar
• SCHWARZ MJ, RIEDEL M, GRUBER R et al.: Levels of soluble adhesion molecules schizophrenia: Relation to psychopathology. In: Psychiatry, Psychoneuroimmunology and Viruses. N Muller (Ed.), Springer Verlag Wien, NY, USA (1999):121–130.
   Google Scholar
• MOLLER N, RIEDEL M, C et al.: Beneficial anti-psychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. Psychiatry (2002) 159:1029–1034.
   PubMed Web of Science ®Google Scholar
• ••The first clinical study showing atherapeutic influence of COX-2 inhibition on schizophrenia.
   Google Scholar
• MOLLER N, DOBMEIER P, EMPEL M et al.: Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. Ear. Psychiatry (1997) 12:294–299.
   PubMed Web of Science ®Google Scholar
• PYEON D, DIAZ FJ, SPLITTER GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. Vim]. (2000) 74:5740–5745.
   Google Scholar
• BISHOP-BAILEY D,-GAFFNEY A, HELLEWELL PG et al.: Cyclooxygenase-2 regulates inducable ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (1998) 249:44–47.
   Google Scholar
• MOLLER N, RIEDEL M, SCHWARZ MJ et al.: Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Ear. Arch. Psychiatry Clin. Neurosci (In press).
   Google Scholar
• MOLLER N, ACKENHEIL M: Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: The relationship to negative symptomatology. Schizophrenia Res. (1995) 14:223–228.
   PubMed Web of Science ®Google Scholar
• DICKERSON FB, BORONOW JJ, STALLINGS C et al.: Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry (2003) 60:466–472.
   PubMed Web of Science ®Google Scholar
• TEUNISSEN CE, VAN BOXTEL MP, BOSMA H et al.: Inflammation markers in relation to cognition in a healthy aging population. I Neuroimmunol (2003) 134:142–150.
   PubMed Web of Science ®Google Scholar
• SCALI C, GIOVANNINI MG, PROSPERI C et al.: The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects neurons from excitotoxic degeneration in vivo. Neuroscience (2003) 117:909-919. study focusing on the neuroprotective effects of COX-2 inhibitors.
   Google Scholar
• GIOVANNINI MG, SCALI C, PROSPERI C et al.: P-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis. (2002) 11:257–274.
   PubMed Web of Science ®Google Scholar
• ANDREASSON KI, SAVONENKO A, VIDENSKY S et al.: Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. .1. Neurosci. (2001) 21:8198–8209.
   Google Scholar
• •This paper focuses on the role of COX-2 inhibition in cognition.
   Google Scholar
• YERMAKOVA A, OTANION MK: Cyclooxygenases in the central nervous system: Implications for treatment of neurological disorders. Curr. Pharmaceutical Design (2000) 6:1755–1776.
   PubMed Web of Science ®Google Scholar
• BAIK EJ, KIM EJ, LEE SH et al: Cyclooxygenase-2 seletive inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. (1999) 843:118–129.
   PubMed Web of Science ®Google Scholar
• NOGAWA S, ZHANG F, ROSS ME et al: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage.j Neurosci. (1997) 17:2746–2755.
   PubMed Web of Science ®Google Scholar
• VAN WEST D, MAES M: Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuroendocrinol Lett. (1999) 20:11–17.
   PubMedGoogle Scholar
• •A comprehensive overview of the role of inflarnrnation in depressive disorders.
   Google Scholar
• MOLLER N, SCHWARZ J: Immunology in anxiety and depression. In: Handbook of depression and anxiety (2nd Edition). S Kasper, JA den Boer, JMA Sitsen (Eds), Marcel Dekker, NY, USA(2002) 267–288.
   Google Scholar
• DUNBAR PR, HILL J, NEALE TJ et al: Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with. Psycho]. Med. (1992) 22:1051–1057.
   PubMed Web of Science ®Google Scholar
• MAES M, SCHARPE S, MELTZER HY et al.: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. (1994) 54:143–160.
   PubMed Web of Science ®Google Scholar
• MAES M, SCHARPE S, MELTZER HY et al.: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. (1993) 49:11–27.
   PubMed Web of Science ®Google Scholar
• •One of the studies showing increased IL-6 levels in depression.
   Google Scholar
• MAES M, MELTZER HY, BOSMANS E et al.: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Affect. Disord. (1995) 34:301–309.
   PubMed Web of Science ®Google Scholar
• MAES M, BOSMANS E, DE JONGH R et al.: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine (1997) 9:853–858.
   Google Scholar
• SLUZEWSKA A, RYBAKOWSKI J, BOSMANS E et al.: Indicators of immune activation in major depression. Psychiatry Res. (1996) 64:161–167.
   PubMed Web of Science ®Google Scholar
• SONG C, LIN A, BONACCORSO S et al.: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. Affect. Disord. (1998) 49:211–219.
   PubMed Web of Science ®Google Scholar
• BERK M, WADEE AA, KUSCHKE RH et al.: Acute phase proteins in major depression." Psychosom. Res. (1997) 43:529–534.
   Google Scholar
• CALABRESE JR, SKWERER AG, BARANA B et al: (1986) Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 17:41–47.
   PubMed Web of Science ®Google Scholar
• LINNOILA M, WHORTON R, RUBINOW DR et al.: CSF prostaglandin levels in depressed and schizophrenic. Arch. Gen. Psychiatry (1983) 40:405–406.
   PubMed Web of Science ®Google Scholar
• •A classic study reporting increased prostaglandin levels in the CSF of depressive patients.
   Google Scholar
• NISHINO S, UENO R, OHISHI K et al: Salivary prostaglandin concentrations: possible state indicators for major depression. Am. j Psychiatry (1989) 146:365–368.
   PubMed Web of Science ®Google Scholar
• SONG C, LEONARD B: Fundamentals of psychoneuroimmunology J Wiley and Sons (Eds), Chichester, NY, USA (2000).
   Google Scholar
• OHISHI K, UENO R, NISHINO S et al: Increased level of salivary prostaglandins in patients with major depression. Biol. Psychiatry (1988) 23:326–334.
   PubMed Web of Science ®Google Scholar
• CAO C, MATSUMURA K, OZAKI M et al.: Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells." Neurosci. (1999) 19:716–725.
   Google Scholar
• COLLANTES-ESTEVES E,-PERREZ CH: Improved self-control of ostheoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in spain. Carr: Med. Res. Opin. (2003) 19:402–410.
   PubMed Web of Science ®Google Scholar
• ••The first study showing a clinicalantidepressant effect of a COX-2 inhibitor.
   Google Scholar
• SANDRINI M, VITALE G, PINI LA: Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm. Res. (2002) 51:154–159.
   PubMed Web of Science ®Google Scholar